Back to search
FDAFDA · Food and drugs·Recall number D-0165-2023

Rifampin Capsules USP, 300 mg, 100 Capsules (10 x 10) per carton, Rx Only, Distributed by: American Health Packaging, Columbus, Ohio 43217, Carton NDC 60687-586-01 (Individual Dose NDC: 60687-586-11)

Published January 25, 2023 · Recall initiated: December 20, 2022

Summary

FDA records drug Class II recall D-0165-2023, published January 25, 2023 and initiated December 20, 2022. Recalling firm: Amerisource Health Services LLC; Status: Terminated; Reported quantity: 3,091 cartons; Lot: Lot #: 1007805, exp. 12/31/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradations Specifications

What to do

Voluntary: Firm initiated · Letter

Get an email if RIFAMPIN has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
RIFAMPIN
Manufacturer
Amerisource Health Services LLC
Distributor
Nationwide in the USA.
Lot
Lot #: 1007805, exp. 12/31/2023
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Rifampin Capsules USP, 300 mg, 100 Capsules (10 x 10) per carton, Rx Only, Distributed by: American Health Packaging, Columbus, Ohio 43217, Carton NDC 60687-586-01 (Individual Dose NDC: 60687-586-11) recalled?

Yes. FDA published recall D-0165-2023 on January 25, 2023. Reported hazard: Failed Impurities/Degradations Specifications

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: RIFAMPIN.